Continuous ovarian stimulation: a proof-of-concept study exploring the uninterrupted use of corifollitropin α in DuoStim cycles for enhanced efficiency and patient convenience (Alicante protocol)
Juan Carlos Castillo M.D., Ph.D. , Ana Fuentes M.D. , Jose Antonio Ortiz M.Sc., Ph.D. , Esther Abellán M.Sc. , Andrea Bernabeu M.D., Ph.D. , Rafael Bernabeu M.D., Ph.D.
{"title":"Continuous ovarian stimulation: a proof-of-concept study exploring the uninterrupted use of corifollitropin α in DuoStim cycles for enhanced efficiency and patient convenience (Alicante protocol)","authors":"Juan Carlos Castillo M.D., Ph.D. , Ana Fuentes M.D. , Jose Antonio Ortiz M.Sc., Ph.D. , Esther Abellán M.Sc. , Andrea Bernabeu M.D., Ph.D. , Rafael Bernabeu M.D., Ph.D.","doi":"10.1016/j.xfre.2024.03.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To explore the use of weekly continuous dosing of corifollitropin α in DuoStim cycles.</p></div><div><h3>Design</h3><p>Pilot-matched case-control study.</p></div><div><h3>Setting</h3><p>Private fertility center.</p></div><div><h3>Patient(s)</h3><p>Cases were defined as DuoStim cycles performed from November 2022 to May 2023 receiving weekly continuous dosing of corifollitropin α (n = 15). Controls were chosen from a database comprising DuoStim cycles conducted at our institution during the years 2021/2022. Matching was done on a 1-to-1 basis, based on antimüllerian hormone values (±0.4 pmol/L) and age (n = 15).</p></div><div><h3>Intervention(s)</h3><p>Injections of corifollitropin α once every 8 days, along with uninterrupted oral administration of micronized progesterone 200 mg/d (for luteinizing hormone surge prevention) throughout the follicular and luteal phases for ovarian stimulation. Oocyte retrieval.</p></div><div><h3>Main outcome measure(s)</h3><p>Total number of cumulus-oocyte complexes and metaphase II oocytes obtained in follicular + luteal phase stimulation. Secondary outcomes evaluated fertilization rates, number of blastocysts, days of stimulation, number of injectables required, and gonadotropin cost.</p></div><div><h3>Result(s)</h3><p>The study group achieved similar total oocyte and MII yield vs. daily follicle-stimulating hormone protocol (13.3 ± 6.9 vs. 11.8 ± 6.1 and 10.4 ± 6.3 vs. 9.2 ± 4.6, respectively). All secondary outcomes showed no significant differences. The study group experienced a significant reduction of injections to complete a DuoStim cycle (4.5 ± 1.4 vs. 35.2 ± 12.2; mean deviation -30.7; 95% confidence interval, −37.5– to −23.9)].</p></div><div><h3>Conclusion(s)</h3><p>Corifollitropin α on a weekly basis throughout a DuoStim cycle yields an equivalent number of oocytes as standard daily follicle-stimulating hormone administration while drastically reducing the number of required injections.</p></div><div><h3>Trial registration number</h3><p>NCT05815719. EudraCT: 2022-003177-32.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 176-182"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000461/pdfft?md5=d3eeaf7fd8d09fd64e65748138c7478a&pid=1-s2.0-S2666334124000461-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FS Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666334124000461","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To explore the use of weekly continuous dosing of corifollitropin α in DuoStim cycles.
Design
Pilot-matched case-control study.
Setting
Private fertility center.
Patient(s)
Cases were defined as DuoStim cycles performed from November 2022 to May 2023 receiving weekly continuous dosing of corifollitropin α (n = 15). Controls were chosen from a database comprising DuoStim cycles conducted at our institution during the years 2021/2022. Matching was done on a 1-to-1 basis, based on antimüllerian hormone values (±0.4 pmol/L) and age (n = 15).
Intervention(s)
Injections of corifollitropin α once every 8 days, along with uninterrupted oral administration of micronized progesterone 200 mg/d (for luteinizing hormone surge prevention) throughout the follicular and luteal phases for ovarian stimulation. Oocyte retrieval.
Main outcome measure(s)
Total number of cumulus-oocyte complexes and metaphase II oocytes obtained in follicular + luteal phase stimulation. Secondary outcomes evaluated fertilization rates, number of blastocysts, days of stimulation, number of injectables required, and gonadotropin cost.
Result(s)
The study group achieved similar total oocyte and MII yield vs. daily follicle-stimulating hormone protocol (13.3 ± 6.9 vs. 11.8 ± 6.1 and 10.4 ± 6.3 vs. 9.2 ± 4.6, respectively). All secondary outcomes showed no significant differences. The study group experienced a significant reduction of injections to complete a DuoStim cycle (4.5 ± 1.4 vs. 35.2 ± 12.2; mean deviation -30.7; 95% confidence interval, −37.5– to −23.9)].
Conclusion(s)
Corifollitropin α on a weekly basis throughout a DuoStim cycle yields an equivalent number of oocytes as standard daily follicle-stimulating hormone administration while drastically reducing the number of required injections.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
